

REMARKS

The Examiner has required restriction to one of 10 groups:

- I. Claims 1-9 and 42-45, drawn to a method of treating insulin-resistance or hypoinsulinemia comprising administering an antagonist of Dkk-1;
- II. Claims 10-16 and 30-35, drawn to a method of detecting insulin resistance or hypoinsulinemia;
- III. Claims 17-22 and 46, drawn to kits comprising an antagonist of Dkk-1;
- IV. Claims 23-25, drawn to a hybridoma and an antibody;
- V. Claims 26-29, drawn to a method of treating obesity or hyperinsulinemia;
- VI. Claims 36-38, drawn to a kit comprising Dkk-1;
- VII. Claims 39-41, drawn to a kit comprising an antibody that binds Dkk-1;
- VIII. Claim 47, drawn to a monoclonal antibody preparation;
- IX. Claims 48-49, drawn to a method of evaluating a candidate pharmaceutical drug for obesity or hypoinsulinemia in a transgenic animal; and
- X. Claims 50-52, drawn to a transgenic animal.

Without acquiescing to the statements made in the Restriction Requirement, Applicants hereby elect the claims of Group I (claims 1-9 and 42-45) for prosecution in the instant application.

SUMMARY

Prosecution of the application on the merits is requested. If the Examiner believes a telephone conference would advance the prosecution of this application, the Examiner is invited to telephone the undersigned at the below-listed telephone number.

Respectfully submitted,



Date: February 22, 2005

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300
Garen J. Gotfredson
Garen J. Gotfredson
Reg. No. 44,722